Sera Prognostics (SERA) Net Income towards Common Stockholders (2020 - 2026)
Sera Prognostics' (SERA) quarterly Net Income towards Common Stockholders came in at -$10.9 million in Q1 2026, down 27.82% YoY from -$15.0 million in Q1 2025, and down 110.34% on a QoQ basis from -$5.2 million in Q4 2025.
Sera Prognostics (SERA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Sera Prognostics (SERA) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$10.9 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 27.82% year-over-year to -$10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.1 million (down 19.74% YoY) and the FY2025 annual result came in at -$118.0 million, down 5.32% from the prior year.
- Net Income towards Common Stockholders slipped to -$10.9 million in Q1 2026, from -$5.2 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.2 million in Q4 2025 to a low of -$12.7 million in Q3 2025.
- A 5-year average of -$9.9 million and a median of -$10.4 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 70.51% — and 2025, when it jumped 41.05%.
- Tracing SERA's Net Income towards Common Stockholders over 5 years: stood at -$10.4 million in 2022, then rose by 23.99% to -$7.9 million in 2023, then slipped by 10.39% to -$8.8 million in 2024, then jumped by 41.05% to -$5.2 million in 2025, then plunged by 110.34% to -$10.9 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$10.9 million (Q1 2026), -$5.2 million (Q4 2025), and -$12.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Sera Prognostics | 108.53 Mn | 108.53 Mn | -20,000.00 | -9.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.23 Mn |
| Mar 31, 2026 | -10.86 Mn |
| Dec 31, 2025 | -5.16 Mn |
| Sep 30, 2025 | -12.65 Mn |
| Jun 30, 2025 | -12.38 Mn |
| Mar 31, 2025 | -8.50 Mn |
| Dec 31, 2024 | -8.76 Mn |
| Sep 30, 2024 | -8.29 Mn |
| Jun 30, 2024 | -8.74 Mn |
| Mar 31, 2024 | -8.92 Mn |
| Dec 31, 2023 | -7.93 Mn |
| Sep 30, 2023 | -7.83 Mn |
| Jun 30, 2023 | -11.47 Mn |
| Mar 31, 2023 | -11.35 Mn |
| Dec 31, 2022 | -10.44 Mn |
| Sep 30, 2022 | -11.21 Mn |
| Jun 30, 2022 | -11.90 Mn |
| Mar 31, 2022 | -12.45 Mn |
| Dec 31, 2021 | -12.02 Mn |
| Sep 30, 2021 | -9.88 Mn |